The Wegener’s granulomatosis treatment market is estimated grow at a CAGR of 5.90% in the forecast period of 2023-2031. The market is expected to grow owing to the increasing prevalence of Wegener’s granulomatosis and improved governmental and private actions to increase understanding about the right diagnosis and treatment of such a rare ailment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
GPA, or granulomatosis with polyangiitis (Wegener's), is a rare blood vessel disease. It is a potentially fatal autoimmune illness with an unclear cause. Since the inflammation in the blood vessel prevents optimal blood flow, the cells do not receive the oxygen they require. This results in tissue damage known as granulomatous inflammation. A granuloma is a form of cellular inflammation that is typically seen in biopsies of damaged organs. The traditional clinical triad includes necrotizing granulomatous inflammation of the upper and/or lower respiratory tract, necrotizing glomerulonephritis, and an autoimmune necrotizing systemic vasculitis that primarily affects tiny arteries.
This rare condition is believed to impact 3 people out of every 100,000. It has an equal impact on males and women. GPA can happen at any age, although it is most common between the ages of 40 and 65. It is uncommon in children.
There is no single exam for determining GPA. Many factors contribute to GPA diagnosis, including symptoms, physical examination, blood testing, and imaging procedures like X-rays, CT scans, or MRI.
Active GPA produces inflammation in the blood vessels and organs. Chronic inflammation in blood arteries or organs can lead to organ failure. Without therapy, GPA can rapidly develop, potentially leading to life-threatening kidney or lung failure.
Those with active severe disease are frequently given a glucocorticoid (steroid) medicine, such as Prednisone in combination with Cyclophosphamide (Cytoxan), a chemotherapy treatment. Prednisone is given at a high dose and progressively tapered off over a period of weeks to months. Cyclophosphamide is administered orally or by injection for three to six months. Those who improve are subsequently shifted to another medicine for 2 or more years, such as Methotrexate (Rheumatrex, Trexall) or Azathioprine (Imuran, Azasan). Prednisone and Methotrexate may be used to treat those with less active illness.
According to the Wegener’s granulomatosis treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis
Market Breakup by Drug
Wegener’s Granulomatosis Treatment Market Breakup by Route of Administration
Market Breakup by Therapeutic Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global prevalence is predicted to be between 1/6,400 and 42,000, with an annual incidence of 1/84,000 to 475,000. There is geographic and/or ethnic variation, with colder places and Caucasians having a higher occurrence. Childhood-onset disease has a female predominance, whereas adult-onset disease has a little male predominance.
The North American region is likely to lead the market throughout the projection period due to the higher incidence rate of Wegener’s granulomatosis. 3 per 100,000 people are affected by Wegener’s granulomatosis.
Due to high prevalence rates, improved healthcare infrastructure and amenities, increased government activities, rising disposable income in this region, expansion of the healthcare system, and increasing approval rates for additional novel medications, the Asia Pacific region is expected to grow at the fastest rate. The market expansion is being driven by the region’s rapidly expanding healthcare infrastructure, particularly in China and India, and the region’s increased awareness of rare disease treatment.
Clinical studies and increased R&D spending have allowed for the introduction of novel medicine molecules to the market. The companies are developing potential drug options to improve the treatment of GPA.
Additionally, enhanced governmental and private actions to increase information regarding correct diagnosis and treatment of such a rare ailment, technology improvements, increased public health awareness, and favourable reimbursement rules will boost the market expansion.
The increased use of monoclonal antibodies and recent advances in systemic treatment of Wegener's granulomatosis, including the introduction of investigational immunosuppressive drugs, such as Etanercept, Leflunomide, and Deoxyspergualin, are expected to shift the conventional treatment paradigm.
ChemoCentryx, Inc. gained USFDA approval for TAVNEOS (avacopan) in October 2021. It is used to treat adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), specifical Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is an orally administered selective complement 5a receptor inhibitor used in conjunction with conventional therapy.
The report gives an in-depth analysis of the key players involved in the Wegener’s granulomatosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis Method||
|Breakup by Drug Classification||
|Breakup by Route of Administration||
|Breakup by Therapeutic Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Wegener's Granulomatosis Disease Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation
6.1 Emerging Therapies and Clinical trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
126.96.36.199 Patent Status and Expiry
188.8.131.52 Timelines from Drug Development to Commercial Launch
184.108.40.206 New Drug Application
220.127.116.11.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
18.104.22.168 US FDA
22.214.171.124 EU EMA
126.96.36.199 INDIA CDSCO
188.8.131.52 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Global Wegener's Granulomatosis Treatment Market
8.1 Global Wegener's Granulomatosis Treatment Market Overview
8.2 Global Wegener's Granulomatosis Treatment Market Analysis
8.2.1 Market Overview
184.108.40.206 Global Historical Wegener's Granulomatosis Treatment Market Historical Value (2016-2022)
220.127.116.11 Global Forecast Wegener's Granulomatosis Treatment Market Forecast Value (2023-2031)
8.2.2 Global Wegener's Granulomatosis Treatment Market by Diagnosis Method
18.104.22.168 Market Overview
22.214.171.124.1 Lab Test
126.96.36.199.1.1 Blood Test
188.8.131.52.1.2 Urine Test
184.108.40.206.2 Imaging tests
220.127.116.11.2.1 Chest X-rays
18.104.22.168.2.2 CT Scan
8.2.3 Global Wegener's Granulomatosis Treatment Market by Drug Classification
22.214.171.124 Market Overview
126.96.36.199.2 Plasma Exchange
8.2.4 Global Wegener’s Granulomatosis Treatment Market by Route of Administration
188.8.131.52 Market Overview
8.3 Global Wegener's Granulomatosis Treatment Market by Therapeutic Channel
8.3.1 Market Overview
8.4 Global Wegener's Granulomatosis Treatment Market by Region
8.4.1 Market Overview
184.108.40.206 North America
220.127.116.11 Asia Pacific
18.104.22.168 Latin America
22.214.171.124 Middle East and Africa
9 North America Wegener’s Granulomatosis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Wegener’s Granulomatosis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Wegener’s Granulomatosis Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Wegener’s Granulomatosis Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Wegener’s Granulomatosis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Wegener's Granulomatosis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Market Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sonoma Pharmaceuticals, Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 GSK plc
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Halozyme Therapeutics, Inc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Sun Pharmaceutical Industries
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Teva Pharmaceutical Industries
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Aprogen, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Amgen, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Epirus Biopharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Pfizer Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Novartis AG
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
16 Global Wegener's Granulomatosis Treatment Market- Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market is likely to grow at a CAGR of 5.90% during the forecast period of 2023-2031.
The market is expected to witness significant growth owing to the increasing prevalence of Wegener’s granulomatosis, improved actions to increase understanding about the right diagnosis and treatment of such a rare ailment, technology improvements, an increase in public health awareness, and favourable reimbursement regulations.
North America is the dominating region in the market owing to the rising demand for the market.
Sonoma Pharmaceuticals, Inc., GSK plc, Halozyme Therapeutics, Inc, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Aprogen, Inc., Amgen, Inc., Epirus Biopharmaceuticals, Inc., Pfizer Inc., and Novartis AG, among others, are the leading companies in the market.
Yes, Wegener’s is an autoimmune disease. There is currently no cure but early diagnosis and adequate treatment can put the disease into relapse, allowing many patients to live full, productive lives. GPA, if left untreated, can cause possibly fatal organ damage or failure.
A tissue biopsy is required to confirm the diagnosis of Wegener granulomatosis. Biopsies of the upper respiratory tract reveal acute and chronic inflammation with granulomatous alterations. Kidney biopsies generally reveal segmental necrotizing pauci-immune glomerulonephritis, which is frequently angiocentric.
Pulmonologist (lung specialist); an otolaryngologist (ear, nose, and throat specialist); a nephrologist (kidney specialist); or a bone and joint specialist (rheumatologist) should be consulted to manage Wegener’s granulomatosis.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.